Cited by 1,547Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Desforges, Jane F., Gordon, David J., Rifkind, Basil M.·1989·New England Journal of Medicine

DOI 10.1056/nejm198911093211907

Open this paper in CoChat — free account

Abstract

DESPITE early observations suggesting an inverse relation between serum levels of high-density lipoprotein (HDL) cholesterol and coronary disease,1 2 3 the possible protective role of HDL in atherogenesis received little attention until its "rediscovery" by Miller and Miller4 in 1975 and the publication of confirmatory results from the Honolulu,5 Framingham,6 and Tromsø7 heart studies in 1976 and 1977. In the ensuing decade, research into the biochemistry, metabolism, epidemiology, and genetics of HDL has expanded rapidly, but many questions remain unanswered. The recent publication of the results of the Helsinki Heart Study8 , 9 — in which simultaneous 11 percent increases in HDL and reductions . . .

Integrity signals

Registry

Crossref · 10.1056/nejm198911093211907

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Self-citation
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,396
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man.
Mattson, F. H., & Grundy, S. M. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34389-3 · Cited by 1,354

Show all 50 references

Research works printed but not linked: 10

Gofman, 1954, Plasma, 2, 413
Hulley, 1977, JAMA, 238, 2269, 10.1001/jama.1977.03280220037017 · DOI
Ernst, 1980, Circulation, 62, IV-41
Sacks, 1985, JAMA, 254, 1337, 10.1001/jama.1985.03360100087019 · DOI
Davis, 1980, Circulation, 62, IV-24
Enger, 1979, Artery, 5, 170
Levy, 1987, Circulation, 76, IV-167
Superko, 1986, JAMA, 256, 2714, 10.1001/jama.1986.03380190084030 · DOI
Hunninghake D, Gordon DJ, Tamir I, Rifkind BM. Management of hyperlipidemia. In: Pradhan SN, Maickel RP, Dutta SN, eds. Textbook of pharmacology. Bethesda, Md.: SP Press International, 1986:617–33.
Castelli, 1986, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 · DOI

Sorted by citations

Items 901–1,000 of 1,000

Electrochemical study of the interaction between cytochrome P450sccK201E and cholesterol
Antonini, M. (2003) · Talanta · doi:10.1016/j.talanta.2003.10.023 · Cited by 18
HDL cholesterol levels in patients with molecularly defined familial hypercholesterolemia.
Miltiadous, G. A., Cariolou, M. A., & Elisaf, M. (2002) · PubMed · Cited by 18
Oxidative Stress in Cardiovascular Disease
Aviram, M., & Rosenblat, M. (2003) · Oxidative stress and disease · doi:10.1201/9780203912874.ch25 · Cited by 18
Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease
Saku, K., Zhang, B., Shirai, K., Jimi, S., Yoshinaga, K., & Arakawa, K. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00372-1 · Cited by 18
Serum Lipid Physiology and the Influence of Glaucoma Medications
Stewart, W. C., & Osterman, J. (1998) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00030-7 · Cited by 17
Inhibition of platelet function by high-density lipoprotein from a patient with apolipoprotein E deficiency
Higashihara, M., Kinoshita, M., Kume, S., Teramoto, T., & Kurokawa, K. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)92084-w · Cited by 18
Transcriptional regulation of the apoAl gene by hepatic nuclear factor 4 in yeast
Fuernkranz, H. A., Wang, Y., Karathanasis, S. K., & Mak, P. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.25.5665 · Cited by 18
Characterization of High‐density Apolipoprotein Particles A‐I and A‐I:A‐II Isolated from Humans with Cholesteryl Ester Transfer Protein Deficiency
Duverger, N., Rader, D. J., Ikewaki, K., Nishiwaki, M., Sakamoto, T., Ishikawa, T., Nagano, M., Nakamura, H., & Brewer, H. B. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20367.x · Cited by 18
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease
Rasnake, C. M., Trumbo, P. R., & Heinonen, T. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.00010.x · Cited by 16
Increased Serum Cholesterol Esterification Rates Predict Coronary Heart Disease and Sudden Death in a General Population
Tanaka, S., Yasuda, T., Ishida, T., Fujioka, Y., Tsujino, T., Miki, T., & Hirata, K. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301297 · Cited by 17
“1098 High-density lipoproteins (HDL) are thought to play a central role in reverse cholesterol transport (RCT), which is the uptake of cholesterol from peripheral tissues and its transport to the liver,(1) and many epidemiological studies have shown that a decreased concentration of HDL-cholesterol (HDL-C) is associat…”
Background
High-density lipoprotein induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through sphingosine kinase-2
Xiong, S.-L., Liu, X., & Yi, G. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1941-y · Cited by 17
“HDL, arguably the most potent anti-atherogenic factor in humans, independently predicts epidemiologic risk of cardiovascular events [30].”
Background
Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate
Dilshad, H., Yousuf, R. I., Shoaib, M. H., Jamil, S., & Khatoon, H. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.08.007 · Cited by 18
“Population studies have consistently shown that high-density lipoprotein (HDL) cholesterol levels are a strong independent inverse predictor of cardiovascular disease.(10-14) In the Framingham Heart Study, HDL cholesterol level was more potent as a risk factor for coronary heart disease than was the level of low-densi…”
Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies
Wilkens, T. L., Tranæs, K., Eriksen, J. N., & Dragsted, L. O. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuab102 · Cited by 18
A common functional promoter variant links CNR1 gene expression to HDL cholesterol level
Feng, Q., Vickers, K. C., Anderson, M. P., Levin, M. G., Chen, W., Harrison, D. G., & Wilke, R. A. (2013) · Nature Communications · doi:10.1038/ncomms2973 · Cited by 16
Lipid Lowering Activity of Citri Unshii Pericarpium in Hyperlipemic Rats
Yang, G., Lee, J., Jung, E.-D., Ham, I., & Choi, H. (2008) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923970802279167 · Cited by 17
“Reduced plasma HDL-C levels have been recognized as a very potent independent risk factor for atherosclerotic cardiovascular disease.(17,18) An increased plasma HDL-C level promotes the net movement of cholesterol from extrahepatic tissues back to the liver, thereby reducing the probability of accumulation of choleste…”
Background
Genetic susceptibility to macrovascular complications of type 2 diabetes mellitus
Barakat, K., & Hitman, G. A. (2001) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2001.0151 · Cited by 17
Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim, B. T., & Chong, P. H. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c161 · Cited by 17
Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
Bencharif, K., Hoareau, L., Murumalla, R. K., Tarnus, E., Tallet, F., Clerc, R. G., Gardès, C., Césari, M., & Roche, R. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-75 · Cited by 17
“Thus, low levels of plasma HDL-c increase the cardiovascular risk factor [1].”
Background
Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells
Siripurkpong, P., & Na‐Bangchang, K. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2008.02.010 · Cited by 17
Relationship between high-density lipoprotein cholesterol and the red cell distribution width in patients with coronary artery disease
Avcı, E., Kırış, T., Demirtaş, A. O., & Kadı, H. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0709-5 · Cited by 17
“Reduced levels of HDL-C are associated with an increased risk for coronary artery disease and future cardiovascular events [16].”
Perspective: Cardiovascular Disease in the Postgenomic Era--Lessons Learned and Challenges Ahead
Epstein, J. A., Rader, D. J., & Parmacek, M. S. (2002) · Endocrinology · doi:10.1210/en.143.6.2045 · Cited by 17
“Plasma levels of HDL cholesterol are strongly inversely associated with cardiovascular risk (42).”
High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor
Fukutomi, T., Takeda, Y., Suzuki, S., Ito, T., Joh, T., & Itoh, M. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.130 · Cited by 17
The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells.
Hamilton, K. K., & Sims, P. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115504 · Cited by 17
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Fabbri, G., & Maggioni, A. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0025-6 · Cited by 19
Two Different Allelic Mutations in a Finnish Family With Lecithin:Cholesterol Acyltransferase Deficiency
Miettinen, H. E., Gylling, H., Ulmanen, I., Miettinen, T. A., & KONTULA, K. K. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.4.460 · Cited by 17
Production rate determines plasma concentration of large high density lipoprotein in non-human primates
Colvin, P. L., Moriguchi, E. H., Barrett, P. H. R., Parks, J. S., & Rudel, L. L. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32506-2 · Cited by 17
Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor
Funatsu, T., Kakuta, H., Takasu, T., & Miyata, K. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02611-0 · Cited by 17
Potential for increasing high-density lipoprotein cholesterol, subfractions HDL2-C and HDL3-C, and apoprotein Al among middle-age women
Meilahn, E. N., Kuller, L. H., Matthews, K. A., Wing, R. R., Caggiula, A. W., & Stein, E. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90044-5 · Cited by 17
Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol
Squires, R. W., Allison, T. G., Gau, G. T., Miller, T. D., & Kottke, B. A. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60824-6 · Cited by 17
16-Year incidence of ischemic heart disease in the NHLBI twin study A classification of subjects into high- and low-risk groups
Carmelli, D., Selby, J. V., Quiroga, J., Reed, T., Fabsitz, R. R., & Christian, J. C. (1994) · Annals of Epidemiology · doi:10.1016/1047-2797(94)90097-3 · Cited by 17
Retinoid X receptor homodimers function as transcriptional activators in yeast
Mak, P., Fuernkranz, H. A., Ge, R., & Karathanasis, S. K. (1994) · Gene · doi:10.1016/0378-1119(94)90335-2 · Cited by 17
High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins
Stein, O., Dabach, Y., Hollander, G., Ben-Naim, M., Halperin, G., & Stein, Y. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00006-4 · Cited by 17
HDL’s Protein Cargo
Heinecke, J. W. (2013) · Circulation · doi:10.1161/circulationaha.112.000889 · Cited by 17
“robust evidence that low HDL-C levels associate with clinically significant CVD.(2) Moreover, atherosclerosis increases”
Background
El colesterol HDL: ¿un nuevo objetivo terapéutico en el manejo de las dislipidemias y la ateroesclerosis?
María del Rosario Laris, E., Llona, A. A., Cuevas, A. M., & Rigotti, A. (2005) · Revista médica de Chile · doi:10.4067/s0034-98872005000700011 · Cited by 17
Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance
Mooradian, A. D., & Haas, M. J. (2015) · Drugs · doi:10.1007/s40265-015-0390-1 · Cited by 16
“It has been over 40 years since the observation that low HDL cholesterol (HDLc) is an independent risk of coronary heart disease (CHD), even when low-density lipoprotein cholesterol (LDLc) is low [5].”
Background
Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Julve, J., Llaverías, G., Blanco‐Vaca, F., & Escolá‐Gil, J. C. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111794519264 · Cited by 16
Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients
Suematsu, Y., Goto, M., Park, C., Nunes, A. C. F., Jing, W., Streja, E., Rhee, C. M., Cruz, S., Kashyap, M. L., Vaziri, N. D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00334 · Cited by 16
“While increasing serum concentrations of high density lipoprotein (HDL) cholesterol (HDLC) are associated with reduced risk of all-cause an d CV mortality in the general population (3, 4), in certain subsets of patients, including those with ESRD being treated with hemodialysis, elevated HDL-C levels are paradoxically…”
Background
High-density lipoprotein cholesterol: How High
Sachan, A., Rajagopal, G. M., & Suresh, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104048 · Cited by 18
“It is wellestablished that low concentration of HDL-C is associated with a higher risk of CHD and rising concentrations are associated with a fall in risk of CHD.[2,3] However, how high serum concentration of HDL-C is good enough, is not very clear.”
Background
Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo
Shimizu, T., Tanigawa, H., Miura, S.-I., Kuwano, T., Takata, K., Suematsu, Y., Imaizumi, S., Yahiro, E., Zhang, B., Uehara, Y., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.012 · Cited by 16
Glucocorticoids upregulate high-affinity, high-density lipoprotein binding sites in rat hepatocytes
Bocharov, A. V., Huang, W., Tg, V., Zaitseva, E. V., Frolova, E. G., Rampal, P., & Bertolotti, R. (1995) · Metabolism · doi:10.1016/0026-0495(95)90185-x · Cited by 16
2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy
Sweis, R. F., Hunt, J. A., Kallashi, F., Hammond, M. L., Chen, Y., Eveland, S. S., Guo, Q., Hyland, S. A., Milot, D. P., Cumiskey, A.-M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.090 · Cited by 16
D-4F, an apolipoprotein A-I mimetic, inhibits TGF-β1 induced epithelial-mesenchymal transition in human alveolar epithelial cell
You, J., Wang, J., Xie, L., Zhu, C., & Xiong, J. (2016) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2016.07.005 · Cited by 16
The Effect of T'ai Chi Exercise on Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Alenazi, A. M., Alshehri, M. M., Hoover, J. C., Yabroudi, M. A., Kachanathu, S. J., & Liu, W. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2017.0104 · Cited by 17
“3,4 5–7 In a population-based study, a decrease of 5 mg/dL in HDL-C was associated with a 25% increased risk of myocardial infarction.”
A Study of the Impact of Arabic Coffee Consumption on Serum Cholesterol
Ali, M. E. S., & Felimban, F. (1993) · Journal of the Royal Society of Health · doi:10.1177/146642409311300602 · Cited by 16
Human Cholestryl Ester Transfer Protein (TaqIB) Polymorphism among Filipinos with Cardiovascular Risk Factors
Sy, R. G., Cutiongco, E. M., Punzalan, F. E. R., Santos, R. S., Geronimo, F., & Tangco, R. V. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.116 · Cited by 16
The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux
Bernini, F., Calabresi, L., Bonfadini, G., & Franceschini, G. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00200-6 · Cited by 16
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
Holvoet, P., Danloy, S., Deridder, E., Lox, M., Bernar, H., Dhoest, A., & Collen, D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3038 · Cited by 16
“apo AI-(1-189)apo AII-(12-77)/apo E KO z apo AI/apo E KO mice.”
BackgroundMethodInfluential
SAR studies: Designing potent and selective LXR agonists
Szewczyk, J. W., Huang, S., Chin, J., Tian, J., Mitnaul, L. J., Rosa, R. L., Peterson, L., Sparrow, C. P., & Adams, A. D. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.050 · Cited by 16
Postprandial Lipemia in Postmenopausal Women with High Fasting High-Density Lipoprotein Cholesterol
Kolovou, G. D., Anagnostopoulou, K. K., Salpea, K. D., Pilatis, N. D., Grapsa, G., Pantelakis, A., Tsarpalis, K., Kapnia, E., Cokkinos, D. V., & Iraklianou, S. A. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200601000-00005 · Cited by 16
“765 Smoking ( /-) 0/21 6/9 3/8 Diabetes Mellitus ( /-) 0/21 1/14 0/11 CHD ( /-) 0/21 1/14 0/11 Hypertension ( /-) 1/20 0/15 0/11 TC (mg/dl) 243 (30) 344 (64) 200 (35) 0.”
A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients
KIMURA, H., Gejyo, F., Yamaguchi, T., Suzuki, S., Imura, T., Miyazaki, R., & Arakawa, M. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v102294 · Cited by 16
Hypercholesterolaemia and vascular disease after transplantation
Higgins, R. M., & Ratcliffe, P. J. (1991) · Transplantation Reviews · doi:10.1016/s0955-470x(10)80019-9 · Cited by 16
Self-Supervised Learning-Based General Laboratory Progress Pretrained Model for Cardiovascular Event Detection
Chen, L., Hung, K.-H., Tseng, Y., Wang, H., Lu, T., Huang, W., & Tsao, Y. (2023) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2023.3307794 · Cited by 21
“Conversely, the plasma level of high-density lipoprotein cholesterol (HDL-c) exhibits an inverse relationship with the risk of cardiovascular diseases [49].”
Background
Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis
Wu, B. J., Shrestha, S., Ong, K. L., Johns, D. G., Dunn, L., Hou, L., Barter, P. J., & Rye, K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.014 · Cited by 15
“In fact, previous epidemiological studies have identified an association of higher HDL cholesterol levels with a decreased risk of myocardial infarction and ischemic stroke, as well as improved survival and prognosis after myocardial infarction [22,23].”
Result
Citrulline increases cholesterol efflux from macrophages in vitro and ex vivo via ATP-binding cassette transporters
Uto‐Kondo, H., Ayaori, M., Nakaya, K., Takiguchi, S., Yakushiji, E., Ogura, M., Terao, Y., Ozasa, H., Sasaki, M., Komatsu, T., et al. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-76 · Cited by 15
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents
Shinkai, H. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903198451 · Cited by 15
“Several epidemiological studies have shown that a low level of high-density lipoprotein cholesterol (HDL-C) is a critical determinant of coronary heart disease (CHD) independent of LDL-C levels [2,3].”
Background
Association of endothelial lipase gene−384A/C with coronary artery disease in Han Chinese people
Xie, L., Sun, Y., Yu, T., Liu, Y., & Deng, Y. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007621 · Cited by 15
“Since a moderate linkage disequilibrium was observed between −384A/C and 584C/T polymorphisms in controls (D0=0.3349), we used the PHASE case–control test for detecting the association between haplotypes of the two SNP loci and patients with CAD.”
BackgroundInfluential
Natural human apoA-I mutations L141R Pisa and L159R FIN alter HDL structure and functionality and promote atherosclerosis development in mice
Tiniakou, I., Kanaki, Z., Georgopoulos, S., Chroni, A., Eck, M. V., Fotakis, P., Zannis, V. I., & Kardassis, D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.028 · Cited by 15
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Roy, S. S., Nguyen, H. C. X., Angelovich, T. A., Hearps, A. C., Huynh, D., Jaworowski, A., & Kelesidis, T. (2017) · Journal of Visualized Experiments · doi:10.3791/56325 · Cited by 15
Hypolipidaemic and Antidiabetic Potency of Allium cepa (Onions) Bulb in Alloxan-Induced Diabetic Rats
Airaodion, A. I., Akaninyene, I. U., Ngwogu, K. O., Ekenjoku, J. A., & Ngwogu, A. C. (2020) · Acta Scientifci Nutritional Health · doi:10.31080/asnh.2020.04.0648 · Cited by 15
Pulmonary surfactant protein B carried by HDL predicts incident CVD in patients with type 1 diabetes
Shao, B., Snell‐Bergeon, J. K., Pyle, L. L., Thomas, K. E., de Boer, I. H., Kothari, V. M., Segrest, J. P., Davidson, W. S., Bornfeldt, K., & Heinecke, J. W. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100196 · Cited by 15
“and inverse association of HDL-C levels with CVD risk (5, 6).”
Background
Therapeutic approaches to raising plasma HDL-cholesterol levels
Thompson, M. M., Reed, S., & Cockerill, G. (2004) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0044 · Cited by 15
“In two large, prospective, epidemiologic studies, the Framingham Heart Stud”
Background
In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II
Hannuksela, M. L., Brousseau, M. E., Meyn, S. M., Nazih, H., Bader, G., Shamburek, R. D., Alaupovic, P., & Brewer, H. B. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00200-9 · Cited by 15
“Coronary heart disease risk is inversely correlated with plasma HDL cholesterol concentrations [1].”
Background
Plasma lipid profile, atherogenic and coronary risk indices in some residents of Abeokuta in south-western Nigeria
Ademuyiwa, O., Ugbaja, R. N., & Rotimi, S. O. (2008) · Covenant University Repository (Covenant University) · Cited by 15
Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction
Sigdel, M., Yadav, B. K., Gyawali, P., Regmi, P., Baral, S., Regmi, S. R., & Jha, B. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-640 · Cited by 16
“The association between low levels of HDL-C and an increased risk for CVD has been well established through epidemiological and clinical studies [9].”
Background
Association of Apo E gene polymorphism with HDL level in Tehranian population
DANESHPOUR, M. S., Hedayati, M., Eshraghi, P., & Azizi, F. (2010) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.200900207 · Cited by 15
Oxidised LDL (OxLDL) induces production of platelet derived growth factor AA (PDGF AA) from aortic smooth muscle cells
Cucina, A., Pagliei, S., Borrelli, V., Corvino, V., Stipa, F., Cavallaro, A., & Sterpetti, A. V. (1998) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(98)80220-7 · Cited by 15
S-(2-(Acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors
Maeda, K., Okamoto, H., & Shinkai, H. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.071 · Cited by 15
Cholesteryl Ester Transfer Protein and Atherogenesis
Tall, A. R., SHARP, D., Zhong, S., Hayek, T., Masucci-Magoulas, L., Rubin, E. M., & Breslow, J. L. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb52000.x · Cited by 15
Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy
Polonsky, T. S., & Davidson, M. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.051 · Cited by 15
Cholesteryl Ester Transfer Protein Inhibition
Rensen, P. C. N., & Havekes, L. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000214979.24518.95 · Cited by 15
Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: Receptor expression modulates high-density lipoproteins
Brown, D. R., Brousseau, M. E., Shamburek, R. D., Talley, G. D., Meyn, S. M., Demosky, S. J., Santamarina-Fojo, S., Brewer, H. B., & Hoeg, J. M. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90172-9 · Cited by 15
Influence of macrophage-derived apoprotein E on plasma lipoprotein distribution of apolipoprotein A-I in apoprotein E-deficient mice
Spangenberg, J., & Curtiss, L. K. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(97)00123-9 · Cited by 15
High density lipoprotein-binding proteins in porcine liver. Isolation and histological localization.
de Crom, R., van Haperen, R., Willemsen, R., & van der Kamp, A. W. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.3.325 · Cited by 15
Analysis of the Practice Guidelines of the Dutch College of General Practitioners with Respect to the Use of Blood Tests
van Wijk, M. A. M., Bohnen, A. M., & van der Lei, J. (1999) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.1999.0060322 · Cited by 15
Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol
Bishop, B. M. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828b8463 · Cited by 15
“Additionally, it has been found that for every increase in HDL-C by 1 mg/dL, the risk of coronary heart disease decreases by 2%–3%.(14)”
Background
Lipid pharmacotherapy for treatment of atherosclerosis
Nicholls, S. J., Pisaniello, A. D., Kataoka, Y., & Puri, R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.904287 · Cited by 14
“Population studies consistently demonstrate an inverse relationship between HDLC levels and cardiovascular risk, independent of LDL-C or triglyceride levels [29,30].”
Background
Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients
Israel, A., & Grossman, E. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.030 · Cited by 14
HDL Subclass Analysis in Predicting Metabolic Syndrome in Koreans With High HDL Cholesterol Levels
Yang, H. S., Hur, M., Kim, H., Kim, S. J., Shin, S., Somma, S. D., & the GREAT Network (2020) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.4.297 · Cited by 14
Evacetrapib
Nicholls, S. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0252-3 · Cited by 14
The association between serum albumin levels and related metabolic factors and atrial fibrillation: A retrospective study
Zhao, D., Jiao, H., Zhong, X., Wang, W., & Li, L. (2022) · Medicine · doi:10.1097/md.0000000000031581 · Cited by 14
Isolation of subpopulations of high density lipoproteins: three particle species containing apoE and two species devoid of apoE that have affinity for heparin
Hennessy, L. K., Kunitake, S. T., Jarvis, M., Hamilton, R. L., Endeman, G., Protter, A. A., & Kane, J. P. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37160-1 · Cited by 14
Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study
McDonough, C. W., Gillis, N., Alsultan, A., Chang, S.-W., Kawaguchi‐Suzuki, M., Lang, J. E., Shahin, M. H., Buford, T. W., Rouby, N. M. E., Sá, A. C. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076984 · Cited by 14
“026 mmol/L) decrease in HDL-C is associated with a 2-3% increase in risk for coronary heart disease [5].”
Background
Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists
Ullrich, J. W., Morris, R., Bernotas, R. C., Travins, J. M., Jetter, J. W., Unwalla, R. J., Quinet, E. M., Nambi, P., Feingold, I. B., Huselton, C. A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.031 · Cited by 14
Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice
Johnston, T. P. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.12.0014 · Cited by 14
“Epidemiological studies have clearly established a strong inverse correlation between the concentration of plasma high-density lipoprotein cholesterol (HDL-C) and the incidence of ischaemic heart disease.([1]) Accordingly, the HDL-C level was added to the US National Cholesterol Education Program algorithm for the pre…”
Method
Improving Total-Cholesterol/HDL-Cholesterol Ratio Results in an Endothelial Dysfunction Recovery in Peripheral Artery Disease Patients
Bleda, S., Haro, J. D., Varela, C., Esparza, L., Rodriguez, J., & Acín, F. (2012) · Cholesterol · doi:10.1155/2012/895326 · Cited by 14
“Plasma HDL levels have been inversely related to the incidence of atherothrombotic disease [12, 13].”
Background
Traditional lipoprotein profile: clinical utility, performance requirements, and standardization
Myers, G. L., Cooper, G. R., & Sampson, E. J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90161-9 · Cited by 14
Proteomic Analysis in ob/ob Mice Before and After Hypoglycemic Polysaccharide Treatments
Kim, S. W. (2009) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.0901.056 · Cited by 14
“low high-density lipoprotein (HDL), and small and dense low-density lipoprotein (LDL) in the blood [13].”
Background
Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism
Wollter‐Svensson, L., Stadberg, E., Andersson, K. M., Mattsson, L., Odlind, V., & Persson, I. R. (1995) · Maturitas · doi:10.1016/0378-5122(95)00934-d · Cited by 14
A novel mutation in the intron 1 splice donor site of the cholesterol ester transfer protein (CETP) gene as a cause of hyperalphalipoproteinemia
Jap, T., Wu, Y.-C., Tso, Y.-C., & Chiu, C. (2002) · Metabolism · doi:10.1053/meta.2002.30527 · Cited by 14
Role of Circulating High-Density Lipoprotein and Triglycerides in Coronary Artery Disease: Risk and Prevention
Gordon, D. J. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30326-8 · Cited by 14
Self-citation
Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice
Kawashiri, M., Zhang, Y., Puré, E., & Rader, D. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00103-x · Cited by 14
High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis
Rong, J. X., & Fisher, E. A. A. (2000) · Annals of Medicine · doi:10.3109/07853890009002035 · Cited by 14
Determination of the tissue sites responsible for the catabolism of large high density lipoprotein in the African green monkey
Huggins, K. W., Burleson, E. R., Sawyer, J. K., Kelly, K., Rudel, L. L., & Parks, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34477-1 · Cited by 14
Atherosclerosis goes to the wall
(1992) · The Lancet · doi:10.1016/0140-6736(92)90798-8 · Cited by 14
Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I:A-II and LpA-IV particles from plasma
Duchateau, P. N., Rader, D. J., Duverger, N., Théret, N., Geitere, C. D., Brewer, H. B., Fruchart, J., & Castro, G. R. (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(93)90149-u · Cited by 14
Evidence for impaired cellular cholesterol removal mediated by APO A-I containing lipoproteins in patients with familial lecithin: cholesterol acyltransferase deficiency
Takao, O., Rie, N., Yoichiro, I., Jiri, F., Takata, K., Saito, Y., Horiuchi, S., & Matsuda, I. (1994) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)00056-5 · Cited by 14
Functional genomics of the human high-density lipoprotein receptor scavenger receptor BI
Chadwick, A. C., & Sahoo, D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835ed575 · Cited by 13
The influence of ApoE genotype on the lipid profile and lipoproteins during normal pregnancy in a Southern African population
Tanyanyiwa, D. M., Marais, A. D., Byrnes, P., & Jones, S. (2016) · African Health Sciences · doi:10.4314/ahs.v16i3.28 · Cited by 13
HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study
Butler, A. E., Moin, A. S. M., Reiner, Ž., Sathyapalan, T., Jamialahmadi, T., Sahebkar, A., & Atkin, S. L. (2023) · Cells · doi:10.3390/cells12060855 · Cited by 13
“An inverse association has been reported between high-density lipoprotein cholesterol (HDL-C) and the risk of atherosclerotic coronary artery disease (ASCAD) in multiple clinical and epidemiological studies [14,15], indicative of the protective effect of HDL-C.”
Background
Lipoproteins and other Risk Factors for Cardiovascular Disease in a Student Population
Pap, D., Čolak, E., Majkić‐Singh, N., Grubor‐Lajšić, G., & Vicković, S. (2013) · Journal of Medical Biochemistry · doi:10.2478/jomb-2013-0002 · Cited by 13
“Indeed, each 1% increase in HDL-c concentration has been associated with a 2–4% decrease in the risk for coronary heart disease (20, 21), while an increase of LDL-c concentration of 1 mmol/L leads to increased risk for ischemic heart disease (IHD) by 57% (22).”
Background

Authors: Desforges, J. F., Gordon, D. J., & Rifkind, B. M.
Affiliations: National Heart, Lung, and Blood Institute (US)
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1989-11-09
Volume: 321
Issue: 19
Pages: 1311-1316
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm198911093211907
OpenAlex: W2339616051
Cited by: 1,547
References: 50
Citations by year: 2026: 9 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 13 · 2021: 22 · 2020: 22 · 2019: 30 · 2018: 21 · 2017: 24 · 2016: 36 · 2015: 47 · 2014: 42 · 2013: 42 · 2012: 38
FWCI: 9.17
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: high-density lipoprotein, HDL cholesterol, coronary artery disease, atherogenesis, cardioprotection, HDL metabolism, Helsinki Heart Study
MeSH terms: Coronary Disease, Humans, Lipoproteins, HDL, Cholesterol, HDL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks